Anatomical Therapeutic Chemical • J06BD08 • nirsevimab

A Alimentary tract and metabolism

B Blood and blood forming organs

C Cardiovascular system

D Dermatologicals

G Genito urinary system and sex hormones

H Systemic hormonal preparations, excluding sex hormones and insulins

J Antiinfectives for systemic use

J01 Antibacterials for systemic use

J02 Antimycotics for systemic use

J04 Antimycobacterials

J05 Antivirals for systemic use

J06 Immune sera and immunoglobulins

J06A Immune sera

J06B Immunoglobulins

J06BA Immunoglobulins, normal human

J06BB Specific immunoglobulins

J06BC Other immunoglobulins

J06BD Antiviral monoclonal antibodies

J06BD03 tixagevimab + cilgavimab Indicated for: prevention of COVID-19

J06BD05 sotrovimab Indicated for: COVID-19

J06BD06 regdanvimab Indicated for: COVID-19

J06BD07 casirivimab + imdevimab Indicated for: COVID-19

J06BD08 nirsevimab Indicated for: prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV)

J06BD10 clesrovimab Indicated for: prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants

J07 Vaccines

L Antineoplastic and immunomodulating agents

M Musculo-skeletal system

N Nervous system

P Antiparasitic products, insecticides and repellents

R Respiratory system

S Sensory organs

V Various